Cited by 3,207Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Open access

Amado, Rafael G., Wolf, Michael, Peeters, Marc, Van Cutsem, Eric, Siena, Salvatore, Freeman, Daniel J., Juan, Todd, Sikorski, Robert, Suggs, Sid, Radinsky, Robert, Patterson, Scott D., Chang, David D.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.7116

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.7116

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citation
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483

Flagged first, then by citations

Show all 38 references

Sorted by citations

Items 301–400 of 1,014

Implementing prognostic and predictive biomarkers in CRC clinical trials
Schaeybroeck, S. V., Allen, W. L., Turkington, R. C., & Johnston, P. G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.15 · Cited by 128
A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
Taube, S. E., Clark, G. M., Dancey, J. E., McShane, L. M., Sigman, C. C., & Gutman, S. I. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp334 · Cited by 152
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes
Fumagalli, D., Gavin, P. G., Taniyama, Y., Kim, S. I., Choi, H. J., Paik, S., & Pogue–Geile, K. L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-101 · Cited by 127
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Yokota, T. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799014968 · Cited by 127
Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients
Saridaki, Z., Tzardi, M. N., Papadaki, C., Sfakianaki, M., Pega, F., Kalikaki, A., Tsakalaki, E., Trypaki, M., Messaritakis, I., Stathopoulos, E. N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015980 · Cited by 131
Epidermal growth factor receptor as a biomarker for cervical cancer
Soonthornthum, T., Arias‐Pulido, H., Joste, N. E., Lomo, L. C., Muller, C. Y., Rutledge, T. L., & Verschraegen, C. F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq723 · Cited by 127
Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C. S., Zalcberg, J. R., Simes, J. R., Couture, F., Moore, M. J., Price, T. J., Siddiqui, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.0543 · Cited by 126
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial
Rivera, F., García‐Castaño, A., Vega, N., Vega-Villegas, M. E., & Gutiérrez-Sanz, L. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.113 · Cited by 131
DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset
Berg, M., Danielsen, S. A., Ahlquist, T. C., Merok, M. A., Ågesen, T. H., Vatn, M. H., Mala, T., Sjo, O. H., Bakka, A. O., Moberg, I. O., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013978 · Cited by 129
Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
Okines, A. F. C., Ashley, S. E., Cunningham, D., Oates, J. R., Turner, A., Webb, J., Saffery, C., Chua, Y. J., & Chau, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2847 · Cited by 125
Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention
Pabla, B. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i5.133 · Cited by 132
SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate
Wong, C. C., Qian, Y., Li, X., Xu, J., Kang, W., TONG, J. H. M., To, K., Ye, J., Li, W., Chen, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.011 · Cited by 129
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
EGFR and KRAS in Colorectal Cancer
Markman, B., Ramos, F. J., Capdevila, J., & Tabernero, J. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)51004-7 · Cited by 130
Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
Zhang, J., Zheng, J., Yang, Y., Lu, J., Gao, J., Lu, T., Sun, J. H., Jiang, H., Zhu, Y., Zheng, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep18678 · Cited by 126
KRAS mutations predict response to EGFR inhibitors
Raponi, M., Winkler, H. J. S., & Dracopoli, N. C. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.006 · Cited by 126
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Molecular Target Class Is Predictive of In vitro Response Profile
Greshock, J. D., Bachman, K. E., Degenhardt, Y., Jing, J., Wen, Y. H., Eastman, S. D., McNeil, E., Moy, C. H., Wegrzyn, R. J., Auger, K. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3788 · Cited by 124
The Role of KRAS Mutation Testing in the Management of Patients With Metastatic Colorectal Cancer
Monzon, F. A., Ogino, S., Hammond, M. E., Halling, K. C., Bloom, K. J., & Nikiforova, M. N. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.10.1600 · Cited by 122
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
Dobbin, K. K., Cesano, A., Alvarez, J. D., Hawtin, R. E., Janetzki, S., Kirsch, I. R., Masucci, G. V., Robbins, P. B., Selvan, S. R., STREICHER, H. Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0179-0 · Cited by 125
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
Cherny, N. I., de Vries, E. G. E., Dafni, U. G., Garrett-Mayer, E. S., McKernin, S. E., Piccart, M. J., Latino, N. J., Douillard, J.-Y., Schnipper, L. E., Somerfield, M. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00729 · Cited by 125
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 125
HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
Chou, C., Wu, M., Huang, W., & Chen, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018087 · Cited by 119
Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations
Fischer, M. M., Yen, W.-C., Kapoun, A. M., Wang, M., O’Young, G., Lewicki, J. A., Gurney, A. L., & Hoey, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2817 · Cited by 123
Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 124
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples
Zuo, Z., Chen, S. S., Chandra, P., Galbincea, J. M., Soape, M. P., Doan, S., Barkoh, B. A., Koeppen, H., Medeiros, L. J., & Luthra, R. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.59 · Cited by 119
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Gerdes, C. A., Nicolini, V., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0989 · Cited by 123
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 133
The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
Petrelli, F., Borgonovo, K., & Barni, S. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0257-x · Cited by 124
Neuropilin-1–Dependent Regulation of EGF-Receptor Signaling
Rizzolio, S., Rabinowicz, N., Rainero, E., Lanzetti, L., Serini, G., Norman, J. C., Neufeld, G., & Tamagnone, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0995 · Cited by 120
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
Knickelbein, K., & Zhang, L. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.10.002 · Cited by 124
Master protocol trials in oncology: Review and new trial designs
Hirakawa, A., Asano, J., Sato, H., & Teramukai, S. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.009 · Cited by 120
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
Bianchi, G., Loibl, S., Zamagni, C., Salvagni, S., Raab, G., Siena, S., Laferriere, N., Peña, C. E., Lathia, C. D., Bergamini, L., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832b2ea0 · Cited by 116
Self-citation
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Chan, D. L. H., Segelov, E., Wong, R. S., Smith, A., Herbertson, R. A., Li, B. T., Tebbutt, N. C., Price, T. J., & Pavlakis, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007047.pub2 · Cited by 122
Phenotypic Plasticity, Bet-Hedging, and Androgen Independence in Prostate Cancer: Role of Non-Genetic Heterogeneity
Jolly, M. K., Kulkarni, P., Weninger, K., Orban, J. P., & Levine, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00050 · Cited by 116
KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications
Italiano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0864-z · Cited by 114
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
Hecht, J. R., Cohn, A. L., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, M., Tian, Y., & Go, W. Y. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.009 · Cited by 117
Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
Yang, Y., Zhang, R., Du, J., Yuan, H.-H., Li, Y., Wei, X.-L., Du, X., Jiang, S., & Han, Y. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0660-6 · Cited by 115
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Harandi, A., Zaidi, A., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116
Senior Adult Oncology
Hurria, A., Browner, I. S., Cohen, H. J., Denlinger, C. S., deShazo, M., Extermann, M., Ganti, A. K., Holland, J. C., Holmes, H. M., Karlekar, M. B., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0019 · Cited by 115
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Braun, M. S., & Seymour, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010388342 · Cited by 100
Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
Moosmann, N., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Hass, H. G., Dietzfelbinger, H., Oruzio, D. V., Klein, S., Zellmann, K., Decker, T. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1936 · Cited by 116
A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting
Whitehall, V., Tran, K. L., Umapathy, A., Grieu, F., Hewitt, C., Evans, T., Ismail, T., Li, W. Q., Collins, P., Ravetto, P. F., et al. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.090057 · Cited by 113
A systematic review of treatment guidelines for metastatic colorectal cancer
Edwards, M., Chadda, S., Zhao, Z., Barber, B., & Sykes, D. (2011) · Colorectal Disease · doi:10.1111/j.1463-1318.2011.02765.x · Cited by 113
Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges
Negin, B. P., & Cohen, S. J. (2010) · Current Treatment Options in Oncology · doi:10.1007/s11864-010-0115-3 · Cited by 115
Mutation Detection by Real-Time PCR: A Simple, Robust and Highly Selective Method
Morlan, J., Baker, J. B., & Sinicropi, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004584 · Cited by 114
Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400902802458 · Cited by 113
Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer
Wallin, U., Glimelius, B. L. G., Jirström, K., Darmanis, S., Nong, R. Y., Pontén, F., Johansson, C., Påhlman, L., & Birgisson, H. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.112 · Cited by 111
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
von Einem, J. C., Heinemann, V., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Hass, H. G., Decker, T. W., Klein, S., Held, S., Jung, A., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1678-3 · Cited by 112
Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial
Au, H., Karapetis, C. S., O’Callaghan, C. J., Tu, D., Moore, M. J., Zalcberg, J. R., Kennecke, H. F., Shapiro, J. D., Koski, S. L., Pavlakis, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6048 · Cited by 111
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
Ocvirk, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i25.3133 · Cited by 114
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
Thierry, A. R., Messaoudi, S. E., Mollévi, C., Raoul, J., Guimbaud, R., Pezet, D., Artru, P., Assénat, E., Borg, C., Mathonnet, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx330 · Cited by 114
Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials
Li, R., Zheng, K., Yuan, C., Chen, Z., & Huang, M. (2017) · Nanotheranostics · doi:10.7150/ntno.19380 · Cited by 114
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer
Cremolini, C., Antoniotti, C., Lonardi, S., Aprile, G., Bergamo, F., Masi, G., Grande, R., Tonini, G., Mescoli, C., Cardellino, G. G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5314 · Cited by 116
Targeted therapy for hepatocellular carcinoma
Spangenberg, H. C., Thimme, R., & Blum, H. E. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.86 · Cited by 112
Treatment in advanced colorectal cancer: what, when and how?
Chau, I., & Cunningham, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605061 · Cited by 115
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Xanthakis, I., Sgouros, J., Televantou, D., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-49 · Cited by 111
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2752 · Cited by 110
KRAS Mutation
Franklin, W. A., Haney, J., Sugita, M., Bemis, L., Jimeno, A., & Messersmith, W. A. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.080131 · Cited by 111
Preparation of DNA from cytological material
Dejmek, A., Zendehrokh, N., Tomaszewska, M., & Edsjö, A. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21276 · Cited by 112
Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
Hecht, J. R., Mitchell, E., Neubauer, M. A., Burris, H. A., Swanson, P., Lopez, T., Buchanan, G., Reiner, M., Gansert, J., & Berlin, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2017 · Cited by 110
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
Tougeron, D., Lecomte, T., Pagès, J., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., & Karayan, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds620 · Cited by 115
BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
Oikonomou, E., Koustas, E., Goulielmaki, M., & Pintzas, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2555 · Cited by 113
mTOR pathway: A current, up-to-date mini-review (Review)
Zarogoulidis, P., Lampaki, S., Turner, J. F., Huang, H., Kakolyris, S., Syrigos, K., & Zarogoulidis, P. (2014) · Oncology Letters · doi:10.3892/ol.2014.2608 · Cited by 115
Progress towards personalized medicine
Bates, S. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.001 · Cited by 109
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Perez‐Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño‐García, A., Schalper, K. A., Segura, V., Joaquim Bellmunt, B., Tabernero, J. M., Sweeney, C. J., Choueiri, T. K., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 112
KRAS Mutation Testing in Colorectal Cancer
Plesec, T. P., & Hunt, J. L. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4ed · Cited by 108
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
Baker, J. B., Dutta, D., Watson, D., Maddala, T., Munneke, B., Shak, S., Rowinsky, E. K., Xu, L.-A., Harbison, C. T., Clark, E. A., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606054 · Cited by 110
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
Azzopardi, N., Lecomte, T., Ternant, D., Boisdron-Celle, M., Piller, F., Morel, A., Gouilleux‐Gruart, V., Desvignes, C., Watier, H., Gamelin, E. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1081 · Cited by 110
Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
Boeckx, C., Baay, M. F. D., Wouters, A., Specenier, P. M., Vermorken, J. B., Peeters, M., & Lardon, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0013 · Cited by 110
Self-citation
Biliary tract cancers: current knowledge, clinical candidates and future challenges
Tariq, N.-U.-A., McNamara, M. G., & Valle, J. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s157092 · Cited by 111
Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF
Lang, A. H., Drexel, H., Geller-Rhomberg, S., Stark, N., Winder, T., Geiger, K. D., & Muendlein, A. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.007 · Cited by 107
Pharmacogenetics and Pharmacogenomics: a Bridge to Individualized Cancer Therapy
Weng, L., Zhang, L., Peng, Y., & Huang, R. S. (2013) · Pharmacogenomics · doi:10.2217/pgs.12.213 · Cited by 107
Sensitivity, Specificity, PPV, and NPV for Predictive Biomarkers
Simon, R. M. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv153 · Cited by 107
Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
Voigt, M., Braig, F., Göthel, M., Schulte, A., Lamszus, K., Bokemeyer, C., & Binder, M. (2012) · Neoplasia · doi:10.1593/neo.121242 · Cited by 112
EGFR-targeted therapy
Vecchione, L., Jacobs, B., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.021 · Cited by 109
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
Chu, Q. S.-C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802666397 · Cited by 108
Mechanisms of tumor resistance to EGFR-targeted therapies
Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 109
Integrating predictive biomarkers and classifiers into oncology clinical development programmes
Beckman, R. A., Clark, J., & Chen, C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3550 · Cited by 106
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
Kawazoe, A., Shitara, K., Fukuoka, S., Kuboki, Y., Bando, H., Okamoto, W., Kojima, T., Fuse, N., Yamanaka, T., Doi, T., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1276-z · Cited by 106
Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 110
Self-Assembly of Lithographically Patterned Nanoparticles
Cho, J., & Gracias, D. H. (2009) · Nano Letters · doi:10.1021/nl9022176 · Cited by 108
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer
Winder, T., & Lenz, H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.005 · Cited by 113
Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance
Zhai, Z., Yu, X., Yang, B. J., Zhang, Y., Zhang, L., Li, X., & Sun, H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.033 · Cited by 110
Recent developments in the treatment of metastatic colorectal cancer
Loree, J. M., & Kopetz, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714997 · Cited by 108
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt231 · Cited by 104
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo, S., Bronte, G., Fanale, D., Corsini, L. R., Silvestris, N., Santini, D., Gulotta, G., Bazan, V., Gebbia, N., Fulfaro, F., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70021-9 · Cited by 165
Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data
Kirstein, M. M., Lange, A., Prenzler, A., Manns, M. P., Kubicka, S., & Vogel, A. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0032 · Cited by 105
BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
Li, Z., Zhao, L., Yu, L., & Wei, M. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa022 · Cited by 110
Relationship between 18F-Fluorodeoxyglucose Accumulation and KRAS / BRAF Mutations in Colorectal Cancer
Kawada, K., Nakamoto, Y., Kawada, M., Hida, K., Matsumoto, T., Murakami, T., Hasegawa, S., Togashi, K., & Sakai, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1909 · Cited by 107
Molecular Alterations and Biomarkers in Colorectal Cancer
Grady, W. M., & Pritchard, C. C. (2013) · Toxicologic Pathology · doi:10.1177/0192623313505155 · Cited by 112
A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations
Angulo, B., García-García, E., Martínez, R., Suárez‐Gauthier, A., Conde, E., Hidalgo, M. M., & López‐Ríos, F. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090139 · Cited by 103
Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Manceau, G., Imbeaud, S., Thiébaut, R., Liébaert, F., Fontaine, K., Rousseau, F., Génin, B., Corre, D. L., Didelot, A., Vincent, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2750 · Cited by 105
What should physicians look for in evaluating prognostic gene-expression signatures?
Subramanian, J., & Simon, R. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.60 · Cited by 103
Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases
Margonis, G. A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M. A., & Pawlik, T. M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4587-z · Cited by 101
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Majewski, I. J., & Bernards, R. (2011) · Nature Medicine · doi:10.1038/nm.2311 · Cited by 101

Authors: Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
Affiliations: Ghent University Hospital (BE)
Amgen (United States) (US)
From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
ORCID: Amado, Rafael G.
Peeters, Marc
Siena, Salvatore
Patterson, Scott D.
Chang, David D.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-04-01
Volume: 26
Issue: 10
Pages: 1626-1634
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.7116
OpenAlex: W2106789440
Cited by: 3,207
References: 38
Citations by year: 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
FWCI: 169.59
Type: journal article
Language: en
Update notices: new_edition (2023-06-14)
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders: Amgen
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
MeSH terms: Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks